Advaitaa Ravipati, Tejus Pradeep, Philippe Jean-Pierre, Keyvan Nouri
{"title":"The Practical Side Effects Experienced in Patients Treated With Medications Approved for Melanoma.","authors":"Advaitaa Ravipati, Tejus Pradeep, Philippe Jean-Pierre, Keyvan Nouri","doi":"10.36849/JDD.8368","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Melanoma continues to remain one of the most feared malignancies among patients and dermatologists. Significant strides have been made in expanding the treatment arsenal with systemic medications and immunotherapeutics. With many more drugs available, side effects remain an important component of constructing treatment plans. Using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), cases of real-world side effects reported with melanoma medications were assessed to capture practical patient experiences. Treatments with the highest counts of adverse events were ipilimumab, nivolumab, dabrafenib, and vemurafenib. Individuals reported pyrexia (12.9%), rash (9.8%), diarrhea (9.5%), fatigue (7.0%), and colitis (6.7%) most frequently. Males were more likely to experience pyrexia (aOR 1.1, P=0.006), nausea (aOR 1.4, P<0.001), rash (aOR 1.3, P<0.001), vomiting (aOR 1.2, P=0.005), and headache (aOR 1.3, P<0.001). Females had higher odds of fatigue (aOR 1.2, P=0.002), decreased appetite (aOR 1.2, P=0.004), and dyspnea (aOR 1.3, P<0.001). Patients 62 years old or younger had higher odds of pyrexia (aOR 1.4, P<0.001), nausea (aOR 1.2, P=0.001), vomiting (aOR 1.3, P<0.001), and headache (aOR 2.9, P<0.001). Individuals older than 62 were more likely to report diarrhea (aOR 1.2, P<0.001), fatigue (aOR 1.4, P<0.001), and decreased appetite (aOR 1.5, P<0.001). With patients who have to already digest a difficult diagnosis, the ability to counsel individuals based on the practical side effects of treatments can pave the way for better dialogue and more trust.</p><p><strong>Citation: </strong>Ravipati A, Pradeep T, Jean-Pierre P, et al. The practical side effects experienced in patients treated with medications approved for melanoma. J Drugs Dermatol. 2025;24(5):539-542. doi:10.36849/JDD.8368.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 5","pages":"539-542"},"PeriodicalIF":1.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8368","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Melanoma continues to remain one of the most feared malignancies among patients and dermatologists. Significant strides have been made in expanding the treatment arsenal with systemic medications and immunotherapeutics. With many more drugs available, side effects remain an important component of constructing treatment plans. Using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), cases of real-world side effects reported with melanoma medications were assessed to capture practical patient experiences. Treatments with the highest counts of adverse events were ipilimumab, nivolumab, dabrafenib, and vemurafenib. Individuals reported pyrexia (12.9%), rash (9.8%), diarrhea (9.5%), fatigue (7.0%), and colitis (6.7%) most frequently. Males were more likely to experience pyrexia (aOR 1.1, P=0.006), nausea (aOR 1.4, P<0.001), rash (aOR 1.3, P<0.001), vomiting (aOR 1.2, P=0.005), and headache (aOR 1.3, P<0.001). Females had higher odds of fatigue (aOR 1.2, P=0.002), decreased appetite (aOR 1.2, P=0.004), and dyspnea (aOR 1.3, P<0.001). Patients 62 years old or younger had higher odds of pyrexia (aOR 1.4, P<0.001), nausea (aOR 1.2, P=0.001), vomiting (aOR 1.3, P<0.001), and headache (aOR 2.9, P<0.001). Individuals older than 62 were more likely to report diarrhea (aOR 1.2, P<0.001), fatigue (aOR 1.4, P<0.001), and decreased appetite (aOR 1.5, P<0.001). With patients who have to already digest a difficult diagnosis, the ability to counsel individuals based on the practical side effects of treatments can pave the way for better dialogue and more trust.
Citation: Ravipati A, Pradeep T, Jean-Pierre P, et al. The practical side effects experienced in patients treated with medications approved for melanoma. J Drugs Dermatol. 2025;24(5):539-542. doi:10.36849/JDD.8368.
期刊介绍:
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.